Bock MG

References (3)

Title : Target cell activation of a structurally novel NLRP3 inhibitor NT-0796 enhances potency - Smolak_2024_J.Pharmacol.Exp.Ther__
Author(s) : Smolak P , Nguyen M , Diamond C , Wescott H , Doedens JR , Schooley K , Snouwaert JN , Bock MG , Harrison D , Watt AP , Koller BH , Gabel CA
Ref : Journal of Pharmacology & Experimental Therapeutics , : , 2024
Abstract :
PubMedSearch : Smolak_2024_J.Pharmacol.Exp.Ther__
PubMedID: 38253384

Title : The ester-containing prodrug NT-0796 enhances delivery of the NLRP3 inflammasome inhibitor NDT-19795 to monocytic cells expressing carboxylesterase-1 - Doedens_2024_Biochem.Pharmacol__116455
Author(s) : Doedens JR , Diamond C , Harrison D , Bock MG , Clarke N , Watt AP , Gabel CA
Ref : Biochemical Pharmacology , :116455 , 2024
Abstract :
PubMedSearch : Doedens_2024_Biochem.Pharmacol__116455
PubMedID: 39069136

Title : Discovery of Clinical Candidate NT-0796, a Brain-Penetrant and Highly Potent NLRP3 Inflammasome Inhibitor for Neuroinflammatory Disorders - Harrison_2023_J.Med.Chem_66_14897
Author(s) : Harrison D , Billinton A , Bock MG , Doedens JR , Gabel CA , Holloway MK , Porter RA , Reader V , Scanlon J , Schooley K , Watt AP
Ref : Journal of Medicinal Chemistry , 66 :14897 , 2023
Abstract :
PubMedSearch : Harrison_2023_J.Med.Chem_66_14897
PubMedID: 37874905